On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Human genetic variation
- Public database archive
- dbSNP
- Drug discovery pipeline - implications
- Drug discovery pipeline
- Most efficacious medicines
- Human variation - drug discovery pipeline
- Defining targets
- A good target will play a role in disease pathology
- Family and population based methods
- Genetic association studies
- Evidence for association
- Genes confer low genetic relative risks (GRR)
- Which SNPs to type?
- Haplotype tagging SNPs
- LD, haplotype estimation and tagging SNPs
- The "druggable" genome
- Whole genome by association
- Clinical trials - predicting efficacy and safety
- Phase 1 understanding drug ADME properties
- Azathioprine and chronic inflammatory disease
- Variation and metabolism l
- CYP gene family variation
- Variation and metabolism ll
- Phase 2,3 will it work?
- Atypical anti-psychotics and schizophrenia
- Genome by association list for pharmacogenetics
- Genotyping methods must be high-throughput
- Tagging SNPs efficacy & disease allele frequency
- Magnitude of effect size and multiple testing
- Functional relevance of genetic variation
- Non-synonymous coding SNPs
- Allele specific differential gene expression
- Conserved non-coding sequences (CNC)
- Implication for future treatments
- Redefining disease
- Future treatment approaches
- Increased benefits for patients
- Marketed targeted treatments
- Targeted treatments - overview
- Summary
Topics Covered
- Common variation within the human genome
- The drug discovery pipeline
- The contribution of genetic variation to target identification, validation and clinical development
- Defining drug targets
- Genotype phenotype correlation
- The druggable genome
- Clinical trials
- Whole genome by association methods
- Functional relevance of genetic variation
- Implications for treatments
Links
Series:
Categories:
Talk Citation
John, S. and Davies, N. (2007, October 1). Human genetic variation and therapeutic development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/DKAL1609.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Sally John has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Nick Davies has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.